Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.
Anolin AslanCynthia AslanNaime Majidi ZolbaninReza JafariPublished in: Pneumonia (Nathan Qld.) (2021)
COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients.
Keyphrases
- acute respiratory distress syndrome
- mechanical ventilation
- sars cov
- extracorporeal membrane oxygenation
- coronavirus disease
- intensive care unit
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- respiratory syndrome coronavirus
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- risk assessment
- endothelial cells
- open label
- phase iii